US Patent

US9012469 — Crystalline naloxol-peg conjugate

Composition of Matter · Assigned to AstraZeneca AB · Expires 2032-04-02 · 6y remaining

Vulnerability score 10/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects crystalline forms of naloxol-polyethylene glycol conjugates in oxalate or phosphate salt forms, including methods of preparing them.

USPTO Abstract

Naloxol-polyethlyene glycol conjugates of the formula: are provided in oxalate or phosphate salt forms including crystalline forms. Methods of preparing the salt forms and pharmaceutical compositions comprising the salt forms are also provided.

Drugs covered by this patent

naloxegol-oxalate (NALOXEGOL OXALATE)

Patent Metadata

Patent number: US9012469
Jurisdiction: US
Classification: Composition of Matter
Expires: 2032-04-02
Drug substance claim: Yes
Drug product claim: Yes
Assignee: AstraZeneca AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.